ArticleCommunications medicine2026

Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial.

Alkomiet Hasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.